Furthermore, studies carried out in several models of brain disorders have found that pharmacological blockade or genetic inactivation of A2AR affords a robust neuroprotection [53, 54], and increasing evidence suggests this neuroprotection involves the control of microglia-mediated neuroinflammation [54, 106, 107]. This evidence concerns the gene ADORA2A and brain disorder.